vs
Side-by-side financial comparison of First Western Financial Inc (MYFW) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $27.5M, roughly 1.0× First Western Financial Inc).
The Western Union Company is an American multinational financial services corporation headquartered in Denver, Colorado.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
MYFW vs SPRY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $28.1M |
| Net Profit | — | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | — | -147.6% |
| Net Margin | — | -147.1% |
| Revenue YoY | — | -67.6% |
| Net Profit YoY | — | -182.8% |
| EPS (diluted) | $0.63 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.5M | — | ||
| Q4 25 | $26.7M | $28.1M | ||
| Q3 25 | $26.3M | $32.5M | ||
| Q2 25 | $24.2M | $15.7M | ||
| Q1 25 | $24.8M | $8.0M | ||
| Q4 24 | $24.3M | $86.6M | ||
| Q3 24 | $22.5M | $2.1M | ||
| Q2 24 | $22.8M | $500.0K |
| Q1 26 | — | — | ||
| Q4 25 | $3.3M | $-41.3M | ||
| Q3 25 | $3.2M | $-51.2M | ||
| Q2 25 | $2.5M | $-44.9M | ||
| Q1 25 | $4.2M | $-33.9M | ||
| Q4 24 | $2.7M | $49.9M | ||
| Q3 24 | $2.1M | $-19.1M | ||
| Q2 24 | $1.1M | $-12.5M |
| Q1 26 | — | — | ||
| Q4 25 | 16.6% | -147.6% | ||
| Q3 25 | 15.1% | -163.7% | ||
| Q2 25 | 13.7% | -302.9% | ||
| Q1 25 | 21.6% | -466.3% | ||
| Q4 24 | 16.1% | 54.5% | ||
| Q3 24 | 11.9% | -1051.6% | ||
| Q2 24 | 6.2% | -3068.0% |
| Q1 26 | — | — | ||
| Q4 25 | 12.9% | -147.1% | ||
| Q3 25 | 12.1% | -157.4% | ||
| Q2 25 | 10.3% | -285.6% | ||
| Q1 25 | 16.9% | -425.7% | ||
| Q4 24 | 11.3% | 57.7% | ||
| Q3 24 | 9.5% | -925.0% | ||
| Q2 24 | 4.7% | -2503.2% |
| Q1 26 | $0.63 | — | ||
| Q4 25 | $0.33 | $-0.41 | ||
| Q3 25 | $0.32 | $-0.52 | ||
| Q2 25 | $0.26 | $-0.46 | ||
| Q1 25 | $0.43 | $-0.35 | ||
| Q4 24 | $0.28 | $0.52 | ||
| Q3 24 | $0.22 | $-0.20 | ||
| Q2 24 | $0.11 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $273.4M | $114.3M |
| Total Assets | $3.2B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $273.4M | — | ||
| Q4 25 | $265.6M | $114.3M | ||
| Q3 25 | $261.5M | $147.7M | ||
| Q2 25 | $258.8M | $192.3M | ||
| Q1 25 | $256.6M | $229.0M | ||
| Q4 24 | $252.3M | $256.8M | ||
| Q3 24 | $248.8M | $201.0M | ||
| Q2 24 | $246.9M | $215.2M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $327.7M | ||
| Q3 25 | $3.2B | $372.8M | ||
| Q2 25 | $3.0B | $313.5M | ||
| Q1 25 | $2.9B | $327.3M | ||
| Q4 24 | $2.9B | $351.2M | ||
| Q3 24 | $2.9B | $217.6M | ||
| Q2 24 | $2.9B | $222.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $-43.5M | ||
| Q3 25 | $10.0M | $-47.0M | ||
| Q2 25 | $-9.1M | $-39.6M | ||
| Q1 25 | $8.0M | $-40.7M | ||
| Q4 24 | $606.0K | $42.0M | ||
| Q3 24 | $18.8M | $-14.5M | ||
| Q2 24 | $-11.5M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $9.0M | $-47.2M | ||
| Q2 25 | $-9.7M | $-39.6M | ||
| Q1 25 | $7.0M | $-40.8M | ||
| Q4 24 | $-607.0K | $41.7M | ||
| Q3 24 | $18.6M | $-14.6M | ||
| Q2 24 | $-11.9M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | -21.6% | — | ||
| Q3 25 | 34.1% | -145.4% | ||
| Q2 25 | -39.9% | -252.2% | ||
| Q1 25 | 28.1% | -512.1% | ||
| Q4 24 | -2.5% | 48.2% | ||
| Q3 24 | 82.3% | -706.3% | ||
| Q2 24 | -52.1% | -1463.4% |
| Q1 26 | — | — | ||
| Q4 25 | 14.9% | 0.0% | ||
| Q3 25 | 4.1% | 0.6% | ||
| Q2 25 | 2.4% | 0.3% | ||
| Q1 25 | 4.2% | 1.1% | ||
| Q4 24 | 5.0% | 0.3% | ||
| Q3 24 | 1.3% | 6.8% | ||
| Q2 24 | 1.6% | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | -0.54× | — | ||
| Q3 25 | 3.15× | — | ||
| Q2 25 | -3.63× | — | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 0.22× | 0.84× | ||
| Q3 24 | 8.83× | — | ||
| Q2 24 | -10.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MYFW
| Net Interest Income | $20.9M | 76% |
| Noninterest Income | $6.7M | 24% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
